Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541400 | 0.88 | CALML3 (0.47) | PDE4BPTGDR2GRIN2BMAOAGRM2 | |
| SCHEMBL541401 | 0.88 | CALML3 (0.47) | PDE4BPTGDR2GRIN2BMAOAGRM2 | |
| SCHEMBL541588 | 0.85 | GRM2 (0.46) | GRM2 | |
| SCHEMBL541643 | 0.85 | SCN9A (0.41) | MAOAMAOB | |
| SCHEMBL541639 | 0.84 | PDE4B (0.39) | PDE4BPTGDR2RBP4GRIN2BCHRM4 | |
| SCHEMBL17769268 | 0.76 | GRM2 (0.47) | MAOAGRM2MAOB | |
| SCHEMBL17769267 | 0.76 | GRM2 (0.47) | MAOAGRM2MAOB | |
| SCHEMBL3813623 | 0.75 | CALML3 (0.46) | MAOAMAOBCYP2C19SMN1; SMN2 | |
| SCHEMBL2068861 | 0.74 | SMN1; SMN2 (0.47) | PDE4BGRIN2BFAAHCYP2C19SMN1; SMN2 | |
| SCHEMBL541126 | 0.74 | CALML3 (0.47) | MAOAMAOBCYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| EP-2086968-B1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
| EP-2086968-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008056335-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | PDE4B 3900/4885PTGDR2 3327/4885RBP4 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.